Gold prices bounce off 3-week lows; demand likely longer term
Vicarious Surgical Inc. (NYSE:RBOT), a medical technology company with a market capitalization of approximately $46 million, saw its CEO Adam David Sachs recently sell shares of the company’s Class A common stock, according to a filing with the Securities and Exchange Commission. On June 3, Sachs sold 463 shares at a weighted average price of $7.2193 per share, resulting in a total transaction value of approximately $3,342. The sales were made to cover tax withholding obligations related to the vesting of restricted stock units granted on June 2, 2023. Following the transaction, Sachs holds 50,723 shares of Vicarious Surgical. The company’s stock has declined significantly, dropping over 56% in the past six months, though InvestingPro analysis indicates the company maintains a strong liquidity position with a current ratio of 5.05 and more cash than debt on its balance sheet. Get access to 10+ additional exclusive ProTips and comprehensive analysis through InvestingPro.
In other recent news, Vicarious Surgical Inc. reported its financial results for the first quarter of 2025, revealing an adjusted net loss of $15.3 million, or $2.58 per share. The company noted a 2% decrease in operating expenses compared to the same quarter in the previous year, highlighting a reduction in research and development costs. Vicarious Surgical is advancing its surgical robotic systems and aims to reach clinical-stage status in 2025, with plans to conduct initial human clinical trials later this year. The company is also leveraging strategic partnerships to optimize surgical workflows, including a recent collaboration with UMass Memorial Medical (TASE:BLWV) Center. The financial outlook includes a projected full-year cash burn of $50 million, with a current cash balance of $37 million. Analysts from firms such as BTIG and TD Cowen have been engaging with the company regarding its financial strategies and supply chain management. The company is preparing a technical dossier for regulatory submission by mid-2025 to support its clinical trial plans. Vicarious Surgical continues to focus on disciplined spending and exploring financing options to sustain its operations and development initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.